Cleveland Clinic launched a monthly irAE tumor board in September 2017. The goal was to obtain specialist opinions about the side effects experienced by immunotherapy patients and to review the latest literature from the rapidly evolving field.
The original irAE tumor board consisted of a handful of oncologists and rheumatologists with specific research interest in immune-related toxicities. Since then, the irAE tumor board has grown to include specialists in gastroenterology, endocrinology, cardiology, infectious disease, urology, pulmonology, and hepatology. Additional specialists sit in on meetings if their specific expertise is required. Approximately 15 to 20 people attend each meeting.
